Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
memo - Magazine of European Medical Oncology
Erschienen in:

01.12.2013 | editorial

Neurooncology: current findings and challenges for the future

verfasst von: Silvia Hofer, MD

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 4/2013

Einloggen, um Zugang zu erhalten

Excerpt

Primary central nervous system (CNS) tumors comprise approximately of 120 histological subtypes. Thus, it seems reasonable to concentrate primarily on some common entities. Most primary CNS tumors of adults are of glial origin and if they belong to WHO grade II–IV, they diffusely infiltrate the normal brain ab initio, i.e., pre-therapeutically. With current standard treatment they cannot be cured. And, here lies an immense challenge for the neurooncology community. …
Vorheriger Artikel Antibody–drug conjugates (ADCs)—new targeted therapies
Nächster Artikel ASCO 2013: news in early-stage and advanced breast cancer
Literatur
1.
Louis D, Ohgaki H, Wiestler O, et al. The 2007 WHO classification of tumors of the central nervous system. Acta Neuropathologica. 2007;114:97–109
2.
Cairncross G, Wang M, Shaw E. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol. 2013;20, 31(3):337–43
3.
van den Bent MJ,BAA van, Taphoorn MJ, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol. 2013;20, 31(3):344–50
4.
Wick W, Platten M, Meisner C, et al. NOA-08 Study Group of Neuro-oncology Working Group (NOA) of German Cancer SocietyNOA 08. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol. 2012;13(7):707–15
5.
Malmström A, Grønberg BH, Marosi C, et al. Nordic Clinical Brain Tumour Study Group (NCBTSG). Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol. 2012;13(9):916–26
6.
Northcott PA, Jones DT, Kool M, Robinson GW, Gilbertson RJ, Cho YJ, Pomeroy SL, Korshunov A, Lichter P, Taylor MD, Pfister SM. Medulloblastomics: the end of the beginning. Nat Rev Cancer. 2012;12(12):818–34
7.
Taphoorn MJ, Stupp R, Coens C, Osoba D, Kortmann R, van den Bent MJ, Mason W, Mirimanoff RO, Baumert BG, Eisenhauer E, Forsyth P, Bottomley A,European Organisation for Research and Treatment of Cancer Brain Tumour Group, EORTC Radiotherapy Group, National Cancer Institute of Canada Clinical Trials Group. Health-related quality of life in patients with glioblastoma: a randomized controlled trial. Lancet Oncol. 2005;6(12):937–44
Metadaten
Titel
Neurooncology: current findings and challenges for the future
verfasst von
Silvia Hofer, MD
Publikationsdatum
01.12.2013
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 4/2013
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-013-0091-y

Weitere Artikel der Ausgabe 4/2013

Brentuximab vedotin, a highly active ADC as a new therapeutic option for CD30+ lymphomas

  • short review

Targeted delivery of anticancer agents using antibodies as vectors

  • short review

ASCO 2013—treatment of metastatic melanoma: is it still a story of success?

  • short review

ASCO 2013: news in early-stage and advanced breast cancer

  • short review

ASCO 2013—new concepts and the path to individualized therapy

  • comment

Update on neurooncology Annual meeting of the American Society of Clinical Oncology (ASCO) 2013

  • short review